Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioids Can't Stop Califf Confirmation

This article was originally published in The Pink Sheet Daily

Executive Summary

Commissioner nominee draws overwhelming Senate support – but also bipartisan opposition to FDA's policy on pain products.

You may also be interested in...



OxyContin Repeat? US FDA Seeks To Avoid Fallout Over Butrans Pediatric Data

Advisory committees will discuss whether data from a 41-patient study should be added to Pediatric Use section of labeling for Purdue's buprenorphine product; agency's decision to convene expert panel even though a pediatric indication is not being considered grew out of criticism generated by approval of OxyContin for adolescents.

Gottlieb Closing In On Confirmation Despite Senate Concern On Opioids

US FDA commissioner nominee clears procedural hurdle as agency's opioid policy remains a charged political issue.

FDA's Commissioner Fish Story Continues

US FDA met with a group concerned about seafood consumption advice for pregnant and nursing women; could it satisfy Sen. Murkowski and avoid a hold on Scott Gottlieb's nomination?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel